Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in Soft Tissue Sarcoma With Altered DNA Damage Repair
NCT05515575Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in soft tissue sarcoma (STS) and uterine sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 12 weeks. Started Aug 2022; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
soft tissue sarcoma (STS)uterine sarcoma
Beyond the preview
Go deeper on NCT05515575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515575.